Hydrocortamate

Identification

Generic Name
Hydrocortamate
DrugBank Accession Number
DB00769
Background

Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 475.6175
Monoisotopic: 475.293388049
Chemical Formula
C27H41NO6
Synonyms
  • 17-Hydroxycorticosterone, 21-(diethylamino)acetate
  • Hidrocortamato
  • Hydrocortamate
  • Hydrocortamatum

Pharmacology

Indication

Used topically as an antiinflammatory in the treatment of steroid-responsive dermatoses

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Mechanism of action

Hydrocortamate binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Primarily hepatic via CYP3A4

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Side effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbemaciclibThe metabolism of Abemaciclib can be increased when combined with Hydrocortamate.
AcalabrutinibThe metabolism of Acalabrutinib can be increased when combined with Hydrocortamate.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Hydrocortamate.
AlbendazoleThe metabolism of Albendazole can be increased when combined with Hydrocortamate.
AlectinibThe metabolism of Alectinib can be increased when combined with Hydrocortamate.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Hydrocortamate hydrochloride9QM8U7R83W125-03-1AKQNAIYKSALPKV-OYHXESGYSA-N
International/Other Brands
Etacort (Angelini) / Magnacort (Pfizer) / Ulcort / Ulcort top

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-4-steroids / Delta-4-steroids / Alpha amino acid esters / Alpha-acyloxy ketones / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones
show 8 more
Substituents
11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 20-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Alpha-acyloxy ketone / Alpha-amino acid ester
show 27 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo steroid, glycinyl ester, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid (CHEBI:50851)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Y3N00BK5WK
CAS number
76-47-1
InChI Key
FWFVLWGEFDIZMJ-FOMYWIRZSA-N
InChI
InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1
IUPAC Name
2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl 2-(diethylamino)acetate
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

References

Synthesis Reference

British Patent 879,208; October 4, 1961.

General References
Not Available
Human Metabolome Database
HMDB0014907
PubChem Compound
84088
PubChem Substance
46509076
ChemSpider
75860
ChEBI
50851
ChEMBL
CHEMBL1201263
ZINC
ZINC000004213506
Therapeutic Targets Database
DAP001187
PharmGKB
PA164745515
Wikipedia
Hydrocortamate

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
  • Pfizer laboratories div pfizer inc
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)162-163British Patent 879,208; October 4, 1961.
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0855 mg/mLALOGPS
logP2.82ALOGPS
logP2.32Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)12.61Chemaxon
pKa (Strongest Basic)6.99Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area104.14 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity129.48 m3·mol-1Chemaxon
Polarizability53.53 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9681
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6251
P-glycoprotein substrateSubstrate0.8848
P-glycoprotein inhibitor IInhibitor0.8649
P-glycoprotein inhibitor IIInhibitor0.7043
Renal organic cation transporterNon-inhibitor0.7574
CYP450 2C9 substrateNon-substrate0.8889
CYP450 2D6 substrateNon-substrate0.8473
CYP450 3A4 substrateSubstrate0.7533
CYP450 1A2 substrateNon-inhibitor0.913
CYP450 2C9 inhibitorNon-inhibitor0.8642
CYP450 2D6 inhibitorNon-inhibitor0.7771
CYP450 2C19 inhibitorNon-inhibitor0.8833
CYP450 3A4 inhibitorNon-inhibitor0.6776
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8749
Ames testNon AMES toxic0.8229
CarcinogenicityNon-carcinogens0.9077
BiodegradationNot ready biodegradable0.9903
Rat acute toxicity2.9454 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8902
hERG inhibition (predictor II)Non-inhibitor0.5096
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-000i-9433200000-71a50fe902c19f04fdb3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-056r-1002900000-eb0cd92252484c7b9b87
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-05fr-3309500000-7cbda5faaadb37e95b64
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01q9-8609100000-d17ada108d458402634b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-3523900000-82ea6f03c051f68c4f6f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f6x-9002000000-b2fce30c6c2978fd4c05
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08i4-3913000000-e49b7a5e42cfab1a0ce4
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-232.0836047
predicted
DarkChem Lite v0.1.0
[M-H]-232.9360047
predicted
DarkChem Lite v0.1.0
[M-H]-230.7366047
predicted
DarkChem Lite v0.1.0
[M-H]-210.9564
predicted
DeepCCS 1.0 (2019)
[M+H]+235.0288047
predicted
DarkChem Lite v0.1.0
[M+H]+232.6950047
predicted
DarkChem Lite v0.1.0
[M+H]+229.9077047
predicted
DarkChem Lite v0.1.0
[M+H]+213.48038
predicted
DeepCCS 1.0 (2019)
[M+Na]+234.3853047
predicted
DarkChem Lite v0.1.0
[M+Na]+232.1960047
predicted
DarkChem Lite v0.1.0
[M+Na]+230.6833047
predicted
DarkChem Lite v0.1.0
[M+Na]+220.66368
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. CHADFIELD HW: CORTICOSTEROID THERAPY IN CURRENT DERMATOLOGICAL PRACTICE. Postgrad Med J. 1963 Sep;39:526-33. doi: 10.1136/pgmj.39.455.526. [Article]
  2. Therapeutic regimens for the treatment of immunoinflammatory disorders [Link]
  3. Composition and method for control and treatment of cutaneous inflammation [Link]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at December 02, 2023 06:55